Welcome to Curium Austria

Curium Austria

Leading the way in nuclear medicine

Since 1st June 2021, IASON GmbH and ARGOS Zyklotron Betriebs GesmbH are part of Curium (www.curiumpharma.com), one of the leading companies world-wide for the development, manufacturing and distribution of radiopharmaceutical products that meet industry-leading standards in quality, efficacy and innovation.

The two Austrian pharmaceutical production plants located in Linz and Klagenfurt have since then been successfully integrated into the Curium network and contribute to strengthening our footprint in Europe, enabling us to drive innovation forward. Since May 2022, ARGOS acts as both manufacturer and distributor of all our PET products.

arrow primary arrow ex

Who we are

Curium has a long and proven legacy of serving the radiopharmaceutical market since the 1960s

Market-leading products, best-in-class service, reliability and continual improvements cement our role as the global leader in nuclear medicine. Drawing on our years of experience, we drive the nuclear medicine industry forward through excellence, reliability and unparalleled service.

Curium Austria at a glance

0

PET manufacturing sites in Austria (Linz and Klagenfurt)

0

PET radiopharmaceuticals with Marketing Authorization produced at our Austrian manufacturing sites on a routine basis

4

skilled employees currently working for Curium Austria

0 %

focus on Nuclear Medicine

curium stock image 11

What we do

Trusted to make a difference for patients

We develop, manufacture and distribute radiopharmaceutical products that meet industry-leading standards in quality, efficacy and innovation. We specialize in the production and supply of radioactive tracers used in nuclear medicine. By working to enable accurate early diagnosis and treatment of cancer as well as heart, brain and bone diseases, our world-class products empower our customers with effective treatment and proven patient outcomes.

We believe in building long-term partnerships that drive sustainable growth for our customers. How do we do this? By providing exceptional service reliability By maintaining strict quality standards By constantly innovating and expanding our product portfolio By putting the lives of patients at the forefront of all we do
By continually improving our business, we help our partners to do the same. In turn, we improve the lives and health outcomes of our patients, ensuring a brighter future for all.Our future in nuclear medicine includes new imaging modalities, expansion into new territories, new therapies and groundbreaking new approaches to neuroendocrine tumors and prostate cancer. We will also leverage the power of artificial intelligence to improve image quality and accuracy; to identify patterns to help diagnose pathologies; and of course to better support physicians and nuclear medicine and pharmacy health care professionals. This is just the beginning.The time has come to redefine the experience of cancer. To chart a new path for millions of patients around the world. To provide the necessary nuclear diagnostics and therapies that allow for better lives every day. We achieve this with an honest and transparent approach to the way we conduct business, giving our clients peace of mind and a service they can depend on.We are wholly dedicated to the nuclear medicine industry, working closely with our clinicians and suppliers to stay ahead of trends and deliver effective radiopharmaceutical solutions. We are striving to improve the quality of care and health outcomes through diagnostics and treatment.
Nuclear medicine is a branch of medicine that uses small amounts of radioactive isotopes to help diagnose, determine the severity of, or treat a variety of diseases, including certain types of cancers, heart disease, gastrointestinal, endocrine, neurological disorders and other abnormalities within the body. Because diagnostic nuclear medicine procedures are able to help visualize molecular activity within the body, they offer the potential to identify disease in its earliest stage, often before symptoms occur or before abnormalities can be detected with other diagnostic tests and can even help identify a patient’s response to therapeutic interventions. Larger amounts of radioactive isotopes can also be used for therapy for certain types of diseases.Nuclear medicine diagnostic scans can offer unique information, including details on both the function and anatomic structure of the body and have high sensitivity and specificity for cardiology and oncology.Diagnostic nuclear medicine procedures are non-invasive medical tests that have been used for over 50 years. Depending on the type of nuclear medicine exam, the radiotracer is injected, inhaled, absorbed, or swallowed and accumulates in the organ or area of the body being examined. The isotope then emits radiation from the targeted organ or cell receptor to an external detector, often called a nuclear medicine camera.

We believe in building long-term partnerships that drive sustainable growth for our customers.
How do we do this?
By providing exceptional service reliability
By maintaining strict quality standards
By constantly innovating and expanding our product portfolio
By putting the lives of patients at the forefront of all we do

By continually improving our business, we help our partners to do the same. In turn, we improve the lives and health outcomes of our patients, ensuring a brighter future for all.

Our future in nuclear medicine includes new imaging modalities, expansion into new territories, new therapies and groundbreaking new approaches to neuroendocrine tumors and prostate cancer. We will also leverage the power of artificial intelligence to improve image quality and accuracy; to identify patterns to help diagnose pathologies; and of course to better support physicians and nuclear medicine and pharmacy health care professionals. This is just the beginning.

The time has come to redefine the experience of cancer. To chart a new path for millions of patients around the world. To provide the necessary nuclear diagnostics and therapies that allow for better lives every day. We achieve this with an honest and transparent approach to the way we conduct business, giving our clients peace of mind and a service they can depend on.

We are wholly dedicated to the nuclear medicine industry, working closely with our clinicians and suppliers to stay ahead of trends and deliver effective radiopharmaceutical solutions. We are striving to improve the quality of care and health outcomes through diagnostics and treatment.

Nuclear medicine is a branch of medicine that uses small amounts of radioactive isotopes to help diagnose, determine the severity of, or treat a variety of diseases, including certain types of cancers, heart disease, gastrointestinal, endocrine, neurological disorders and other abnormalities within the body. Because diagnostic nuclear medicine procedures are able to help visualize molecular activity within the body, they offer the potential to identify disease in its earliest stage, often before symptoms occur or before abnormalities can be detected with other diagnostic tests and can even help identify a patient’s response to therapeutic interventions. Larger amounts of radioactive isotopes can also be used for therapy for certain types of diseases.

Nuclear medicine diagnostic scans can offer unique information, including details on both the function and anatomic structure of the body and have high sensitivity and specificity for cardiology and oncology.

Diagnostic nuclear medicine procedures are non-invasive medical tests that have been used for over 50 years. Depending on the type of nuclear medicine exam, the radiotracer is injected, inhaled, absorbed, or swallowed and accumulates in the organ or area of the body being examined. The isotope then emits radiation from the targeted organ or cell receptor to an external detector, often called a nuclear medicine camera.

Building long-term partnerships with our customers by

01

Providing exceptional service reliability

02

Maintaining strict quality standards

03

Constantly innovating and expanding our product portfolio

04

Putting the lives of patients at the forefront of all we do

Advantages of PET/CT Scans with our innovative pharmaceuticals

01

Change of therapeutic concept

02

Better outcome and prognosis of patient

03

Increase of life expectancy and quality of life

04

Cost optimization of patient care

Our Products

Innovative products for our customers

At our two Austrian manufacturing sites, the PET radiopharmaceuticals Efdege®, IASOcholine® (Pcolina®), IASOflu® IASOdopa® and IASOglio® are produced. We hold Marketing Authorizations in many European countries for all of the above mantioned products.
Curium’s global diverse portfolio consists of of more than 50 radiopharmaceutical products – helping to improve the lives of 14 million patients each year.

careers bg
successful,scientists,working,as,a,team,in,the,laboratory

Working for Curium

Career at Curium Austria

Looking for a job at an innovative company? Curium Austria offers an exciting range of careers at the forefront of scientific innovation. Learn more about Curium and the opportunities available.

Innovative products made in Austria

Production of radioactive pharmaceuticals for application in nuclear medicine started at the manufacturing sites in Linz and Klagenfurt in the late 1990s. Our customers are hospitals all across central Europe.

Since June 2021, the two Austrian production sites operate within the European – and indeed world-wide –  network of Curium (see https://www.curiumpharma.com/about/worldwide-offices)

scientists working in the laboratory

Latest news

Do you want to know more about our products?

For inquiries please contact us, we will be happy to assist you!

Find out more about Curium’s global footprint

Scroll to Top
Iason Logo Alt
curium logo

Welcome to our new website

You've been redirected from iason.eu to our new domain curium-austria.com

Curium acquired IASON in June of 2021, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions. Learn more on Curium’s website